There are currently shortages of the Tresiba FlexTouch insulin pen which could affect people living with diabetes who take Tresiba insulin. Here’s what you need to know.
What’s the situation?
Tresiba is a long-acting insulin manufactured by Novo Nordisk. There is no current shortage of the insulin, however there is a shortage which impacts the FlexTouch insulin pen.
Tresiba FlexTouch is a disposable, pre-filled pen designed to be used with pen needles.
Shortages first began in late 2024, and the Department of Health and Social Care expects Tresiba FlexTouch 100units/ml pens to be out of stock in the UK until January 2026.
There are other ongoing insulin shortages - you can find out more here.
Why is there a shortage of Tresiba FlexTouch?
The current shortage is due to higher than expected demand for the pens.
What is the alternative?
Novo Nordisk manufactures Tresiba in 100units/ml cartridges (Penfill), which remain available.
Due to the temporary FlexTouch shortage, your healthcare team might give you the option of continuing to use this insulin in cartridge form, but you will require a re-useable NovoPen that takes the cartridges. Your healthcare team should provide you with a prescription for the pen device and show you how to use it.
Your healthcare team also has the option to consider swapping your Tresiba medication to a suitable alternative, if clinically appropriate.
Jackie Higgins, Senior Clinical Advisor at Diabetes UK, said:
"We ask that healthcare professionals take into account individual’s circumstances and their needs. This should include a discussion to ensure people can continue to manage their treatment and should include a prescription for any new device they need."
More information and support on Tresiba FlexTouch
Ring our helpline with any questions or concerns on 0345 123 2399
Learn more about treating diabetes with tablets and medication.
